$ACDC

Profrac director Dan Wilks buys $2.87m in company stock

ProFrac Holding Corp. (NASDAQ: ACDC) director Dan Wilks acquired $2.87 million in Class A stock in late August 2026, with shares trading at $4.63. The company reported Q2 2026 revenue of $498 million, exceeding estimates, but posted a loss of $2.30 per share over the last year. ProFrac operates with significant debt and is deemed overvalued by InvestingPro.

Original reporting
Published Aug 27, 2026, 1:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 3:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACDC
Bullish
medium confidence
Mentioned
$ACDC
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACDCBullishLow
01

Why it matters

The insider purchase provides fresh data for traders evaluating short‑term momentum.

02

Market read

Primary Form 4 disclosure of insider buying; modest trading relevance for ACDC.

03

What to watch

Company's high debt load and recent loss per share could dampen any upside from the buy.

Relevance 5/10Novelty 6/10Timing: late August 2026 (same‑day filing)

Background

ProFrac Holding Corp. (ACDC) is a U.S. listed oil‑field services company reporting a Q2 loss and modest revenue growth.

Company-level read

Ticker impact

$ACDCBullishMedium confidence
Context

Director Dan Wilks purchased $2.87 million of ACDC Class A shares over three days in late August 2026, increasing his indirect ownership.

Expected impact

Potential modest upside as market absorbs insider demand.

Evidence & confidence

Form 4 filing is a primary source; the purchase size is modest relative to market cap, limiting impact.

Market effects

Limited; reflects confidence in the oil‑field services sector but unlikely to shift broader sentiment.

Minimal impact on U.S. markets.

None

Counterpoint

Insider purchase may be a personal portfolio rebalancing rather than a bullish signal.

Key entities

  • Dan H. Wilks

    Director and 10% owner of ProFrac Holding Corp.

Related articles

$ACDCMed

ProFrac Holding Corp. Reports Second Quarter 2026 Results

ProFrac Holding Corp. (ACDC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 N ews Release Contacts: ProFrac Holding Corp. Austin Harbour – Chief Financial Officer Michael Messina – SVP of Finance investors@pfholdingscorp.com ICR, Inc. PFHoldingsIR@icrinc.com ProFrac Holding Corp. Reports Second Quarter 2026 Results WILLOW PARK, TX – August 6

$ACDCMedAI 9/10

ProFrac, NOV, and Borr Drilling Shares Are Falling, What You Need To Know

Shares of ProFrac (ACDC), NOV (NOV), and Borr Drilling (BORR) fell in the morning session after WTI crude dropped on progress in Iran–US peace-deal talks and renewed hopes for reopening the Strait of Hormuz. The article says lower oil prices typically lead producers to cut capex, reducing demand for drilling and completion services over the next 2–3 quarters.

$ACDCMedAI 9/10

ProFrac (NASDAQ:ACDC) Trading Down 5.5% – Here’s What Happened

ProFrac Holding Corp. (NASDAQ:ACDC) shares fell 5.5% mid-day Wednesday to about $6.82, after closing at $7.22. The stock traded as low as $6.84 on volume of 64,780 shares versus 1.33M average. After its May 7 earnings (EPS -$0.47 vs -$0.37; revenue $449.6M vs $426.4M), analysts cited mixed ratings and targets averaging $6.17.

$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

$EQNRMed

Galp Energia and Equinor Get Offshore Brazilian Oil Block

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.